Bristol Myers Squibb (CELG-RI) Total Non-Current Liabilities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Total Non-Current Liabilities for 18 consecutive years, with $61.0 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Non-Current Liabilities fell 15.6% year-over-year to $61.0 billion; the TTM figure through Jun 2026 stood at $61.0 billion (down 15.6% YoY), while the FY2025 annual figure was $66.5 billion, down 7.33% from the prior year.
• Total Non-Current Liabilities fell to $61.0 billion in Q2 2026 per CELG-RI's latest filing, from $61.5 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $75.8 billion in Q1 2024 and bottomed at $55.6 billion in Q2 2023.
• Historically, Total Non-Current Liabilities has averaged $64.8 billion across 5 years, with a median of $62.8 billion in 2022.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 35.92% — and 2026, when it slipped 15.6%.
• Bristol Myers Squibb's Total Non-Current Liabilities stood at $59.1 billion in 2022, then rose by 0.24% to $59.3 billion in 2023, then climbed by 21.08% to $71.7 billion in 2024, then declined by 7.33% to $66.5 billion in 2025, then declined by 8.3% to $61.0 billion in 2026.
• Business Quant data shows CELG-RI's Total Non-Current Liabilities at $61.0 billion in Q2 2026, $61.5 billion in Q1 2026, and $66.5 billion in Q4 2025.